WellPoint CE Study Results In Coverage Adjustment For Oral Asthma Drugs
Executive Summary
WellPoint lifted prior authorization requirements on oral asthma medications based on the results of a comparative effectiveness analysis of claims data for oral and inhaled asthma medications
You may also be interested in...
Payers’ Use Of Real-World Evidence For Drug Coverage On The Rise – IMS Health
A new study by IMS Health shows payers globally are making more drug reimbursement decisions based on real-world evidence – including 25% of more than 100 identified case studies using biopharma industry-generated data.
CER To Play A Larger Role In Investment Decisions – Merck's McElwee
Pharmaceutical companies are going to need to consider the impact of the growing emphasis on comparative effectiveness earlier in the drug development and investment decision process, Merck & Co.'s Newell McElwee said.
CER To Play A Larger Role In Investment Decisions – Merck's McElwee
Pharmaceutical companies are going to need to consider the impact of the growing emphasis on comparative effectiveness earlier in the drug development and investment decision process, Merck & Co.'s Newell McElwee said.